Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
CAMBRIDGE, Mass. and BEIJING, China, Aug. 30, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the following upcoming investor conferences:
Baird’s 2017 Global Healthcare Conference
Date: Wednesday, September 6, 2017
Time: 12:15 PM ET
Location: New York, NY
Morgan Stanley 15th Annual Global Healthcare Conference
Date: Tuesday, September 12, 2017
Time: 3:30 PM ET
Location: New York, NY
Live webcasts of the presentations can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. Archived replays will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
